Ovarian cancer: A focus on management of recurrent disease

Nature Clinical Practice Oncology

Volumn 3, Issue 11, 2006, Pages 604-611

  Herzog, Thomas J ^a   Pothuri, Bhavana ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; BEVACIZUMAB; BORTEZOMIB; CANFOSFAMIDE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MESNA; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE; TOPOTECAN; TRABECTEDIN; TRASTUZUMAB; XYOTAX;

ACUTE LEUKEMIA; ADVANCED CANCER; ANEMIA; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SIZE; CANCER STAGING; CLINICAL STUDY; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; GYNECOLOGIC SURGERY; HAND FOOT SYNDROME; HUMAN; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PATIENT CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; THERAPY EFFECT; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS;

EID: 33750546483     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0637     Document Type: Review

References (49)

1. Jemal A et al. (2006) Cancer statistics, 2006. CA Cancer J Clin 56: 106-130
2. Bristow RE et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 20: 1248-1259
3. McGuire WP et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6
4. Ozols RF et al. (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21: 3194-3200
5. Vasey PA et al. (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96: 1682-1691
6. Alberts DS et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950-1955
7. Markman M et al. (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19: 1001-1007
8. Armstrong D et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34-43
9. Markman M et al. (2003) Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21: 2460-2465
10. Markman M et al. (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9: 389-393
11. Markman M and Bookman MA (2000) Second-Line treatment of ovarian cancer. Oncologist 5: 26-35
12. Rosenberg P et al. (2002) Randomized trial of single agent paclitaxel given weekly versus every three weeks and with pre-oral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 2002 41: 418-424
13. Herzog TJ (2004) Recurrent ovarian cancer: How important is it to treat to disease progression? Clin Cancer Res 10: 7439-7449
14. Markman M et al. (2004) Liposomal anthracycline treatment for ovarian cancer. Sem Oncol 31 (Suppl 13): 91-105
15. O'Byrne KJ et al. (2002) A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxanenaive relapsed ovarian cancer [abstract]. Proc Am Soc Clin Oncol 21: A808
16. Gordon N et al. (2001) Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3312-3322
17. Gordon AN et al. (2004) Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95: 1-8
18. Kudelka AP et al. (1996) Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14: 1552-1557
19. Creemers GJ et al. (1996) Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 14: 3056-3061
20. Swisher EM et al. (1997) Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 66: 480-486
21. Levy T et al. (2004) Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol 95: 686-690
22. Markman M et al. (2003) Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 90: 593-596
23. Lund B et al. (1995) Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Anticancer Drugs 6 (Suppl 6): 61-62
24. Shapiro JD et al. (1996) Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol 63: 89-93
25. Rose PG et al. (2003) Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum-and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 88: 17-21
26. Schink JC et al. (1995) Altretamine (Hexalen) An effective salvage chemotherapy after paclitaxel (Taxol) in women with recurrent platinum resistant ovarian cancer [abstract]. Proc Am Soc Clin Oncol 14: A770
27. Markman M et al. (1998) Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: A Gynecologic Oncology Group phase II trial. Gynecol Oncol 69: 226-229
28. Rose PG et al. (1998) Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian carcinomas: A Gynecologic Oncology Group study. J Clin Oncol 16: 405-410
29. Markman M et al. (1992) Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 10: 243-248
30. Markman M et al. (1996) Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group ancillary report. Gynecol Oncol 62: 4-6
31. Boehmer CH and Jaeger W (2002) Capecitabine in treatment of platinum-resistant recurrent ovarian cancer. Anticancer Res 22: 439-443
32. Bajetta E et al. (1996) Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 14: 2546-2551
33. Rose PG et al. (2003) A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 88: 130-135
34. Hurwitz H et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
35. Ignoffo RJ (2004) Overview of bevacizumab: A new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm 61: S21-S26
36. Burger RA et al. (2005) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study [abstract]. Proc Am Soc Clin Oncol 24: A5009
37. Bookman MA et al. (2003) Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21: 283-290
38. Aghajanian C (2004) Clinical update: Novel targets in gynecologic malignancies. Semin Oncol 31 (Suppl 16): 22-26
39. Tew KD (2005) TLK-286: A novel glutathione S-transferase-activated prodrug. Expert Opin Investig Drugs 14: 1047-1054
40. D'Incalci M et al. (2003) The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer 39: 1920-1926
41. Markman M et al. (2004) Survival following the documentation of platinum and taxane resistance in ovarian cancer: A single institution experience involving multiple phase 2 clinical trials. Gynecol Oncol 93: 699-701
42. Pfisterer J et al. (2004) Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG [abstract]. Proc Am Soc Clin Oncol 23: A449
43. Parmar MK et al. (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099-2106
44. Chambers SK et al. (1988) Evaluation of the role of second-look surgery in ovarian cancer. Obstet Gynecol 72: 404-408
45. Podratz KC et al. (1988) Evaluation of treatment and survival after positive second-look laparotomy. Gynecol Oncol 31: 9-24
46. Hoskins WJ et al. (1989) Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. Gynecol Oncol 134: 365-371
47. McCreath WA and Chi DS (2004) Surgical cytoreduction in ovarian cancer. Oncology 18: 645-653
48. Thomas GM and Dembo AJ (1993) Integrating radiation therapy into the management of ovarian cancer. Cancer 71: 1710-1718
49. Yap OW et al. (2005) Intraoperative radiation therapy in recurrent ovarian cancer. Int J Radiat Oncol Biol Phys 63: 1114-1121